CDK12 Gene Alterations in Prostate Cancer: Present but Clinically Actionable?

被引：2
|
作者：
Marciscano, Ariel E. [1 ]
Barbieri, Christopher E. [2 ,3 ]
机构：
[1] Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY USA
[2] Weill Cornell Med Coll, Dept Urol, New York, NY USA
[3] Weill Cornell Med Coll, Sandra & Edward Meyer Canc Ctr, New York, NY USA
来源：
EUROPEAN UROLOGY | 2020年 / 78卷 / 05期
关键词：
DNA-REPAIR;
D O I：
10.1016/j.eururo.2020.04.007
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：680 / 681
页数：2
相关论文
共 50 条
  • [31] Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation
    Seung Hyuk Choi
    Seongjae Kim
    Katherine A. Jones
    Experimental & Molecular Medicine, 2020, 52 : 762 - 771
  • [32] Effects of CDK12/13 Inhibition in Patients with Ovarian Cancer
    Hovdar, L.
    Roessler, J.
    Hechenberger, P.
    Rainer, S.
    Ausserlechner, K.
    Greiderer-Kleinlercher, B.
    Ausserlechner, M.
    Marth, C.
    Zeimet, A. G.
    Fiegl, H.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (06) : E25 - E25
  • [33] Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation
    Choi, Seung Hyuk
    Kim, Seongjae
    Jones, Katherine A.
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2020, 52 (05): : 762 - 771
  • [34] Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer
    Dieter, Sebastian M.
    Siegl, Christine
    Codo, Paula L.
    Huerta, Mario
    Ostermann-Parucha, Anna L.
    Schulz, Erik
    Zowada, Martina K.
    Martin, Sylvia
    Laaber, Karin
    Nowrouzi, Ali
    Blatter, Mona
    Kreth, Sina
    Westermann, Frank
    Benner, Axel
    Uhrig, Ulrike
    Putzker, Kerstin
    Lewis, Joe
    Haegebarth, Andrea
    Mumberg, Dominik
    Holton, Simon J.
    Weiske, Joerg
    Toepper, Lena-Marit
    Scheib, Ulrike
    Siemeister, Gerhard
    Ball, Claudia R.
    Kuster, Bernhard
    Stoehr, Gabriele
    Hahne, Hannes
    Johannes, Sarah
    Lange, Martin
    Herbst, Friederike
    Glimm, Hanno
    CELL REPORTS, 2021, 36 (03):
  • [35] CDK12 upregulation and adverse correlation with tumor-associated immune cell infiltrates in prostate cancer
    Hupe, Marie C.
    Offermann, Anne
    Schreiber, Cleopatra
    Merseburger, Axel Stuart
    Perner, Sven
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [36] CDK12 Loss in Prostate Cancer Imparts Poor Prognosis and Limited Susceptibility to Immune Checkpoint Inhibition
    McGregor, Bradley A.
    Wei, Xiao X.
    JCO PRECISION ONCOLOGY, 2020, 4 : 367 - 369
  • [37] Targeting the transcriptional kinases CDK12 and CDK13 in breast and ovarian cancer
    Hamman, Kristin
    Bradley, Michael
    Marineau, Jason
    Choi, Yoon
    Malojcic, Goran
    Orlando, David
    Ren, Yixuan
    Ke, Nan
    Hu, Shanhu
    Olson, Eric
    Fritz, Christian
    Roberts, Christopher
    FASEB JOURNAL, 2017, 31
  • [38] The prevalence of CDK12 alterations in Chinese cancer patients and the association with tumor mutation burden(TMB) and survival.
    Li, Ke
    Guo, Xi
    Mao, Yunhua
    Yang, Mengmei
    Huang, Mengli
    Xie, Wenzhuan
    Liu, Xinyi
    Wang, Dejuan
    Qiu, Jianguang
    Zu, Xiongbing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Targeting the transcriptional kinases CDK12 and CDK13 in breast and ovarian cancer
    Bradley, Michael
    Marineau, Jason
    Choi, Yoon
    Hamman, Kristin
    Malojcic, Goran
    Orlando, David
    Ren, Yixuan
    Ke, Nan
    Hu, Shanhu
    Olson, Eric
    Fritz, Christian
    Roberts, Christopher
    CANCER RESEARCH, 2017, 77
  • [40] Detection of clinically-actionable alterations as hallmarks of de novo small cell prostate cancer.
    Vandekerkhove, Gillian Rae
    Chedgy, Edmund
    Herberts, Cameron
    Annala, Matti
    Fazli, Ladan
    Beltran, Himisha
    Chi, Kim N.
    Wyatt, Alexander William
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345